MRD negativity associated with superior survival outcomes in AML

Achievement of minimal residual disease negativity appeared associated with superior DFS and OS among patients with acute myeloid leukemia, according to results of a meta-analysis published in JAMA Oncology. Researchers observed a consistent benefit of minimal residual disease (MRD) negativity across age groups and AML subtypes, and regardless of time of MRD assessment, specimen source and MRD

Read the full article here

Related Articles